Search the Newsreel

Roadzen Delivers Best Quarter in Company History with Record Q1 FY2027 Revenue of $16.2 Million, Up 49% Year-Over-Year

Roadzen Inc. announced record financial results for Q1 FY2027, with revenue reaching $16.2 million, a 49% increase year-over-year, marking the best quarter in company history. The company also improved its Adjusted EBITDA loss by 73% and reached its second consecutive 'Rule of 40' quarter. …

ZenaTech, Inc. Expands ZenaWorx Drone-Based Construction Monitoring Software to Include Digital Terrain Modeling

ZenaTech, Inc. has expanded its ZenaWorx drone-based construction monitoring software to include digital terrain modeling (DTM) capabilities. This enhancement, offered through its Drone as a Service division, allows for precise measurement of cut-and-fill volumes, grading accuracy, and drainage during the earthworks phase of large …

Apex Frozen Foods Share Price Rises 11.95%: Full Analysis

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

Zentalis Pharmaceuticals prices $80.5M stock offering at $3.50

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) has announced the pricing of an underwritten public offering of 23 million shares of common stock at $3.50 per share, aiming to raise approximately $80.5 million in gross proceeds. The offering is expected to close on August 17, 2026, with …

ZenaTech Expands ZenaWorx Software with Digital Terrain Modeling, Signs First AI Data Center Customer

ZenaTech, Inc. has expanded its ZenaWorx construction monitoring software to include digital terrain modeling (DTM) capabilities, a move designed to enhance precision in large-scale construction projects like AI data centers. The company also announced its first paying customer in the AI data center construction …

ETFs Investing in Citizens Financial Group, Inc. Stocks

This article lists various ETFs that hold Citizens Financial Group, Inc. (CFFG) stocks, providing detailed information such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return. The ETFs cover a range of investment …

Roadzen Inc. 1Q 2026: Revenue $16.19M, EPS $(0.12) — 10-Q Summary

Roadzen Inc. reported its first-quarter 2026 results, showing a 49% increase in revenue to $16.19 million compared to the previous year, while recording a net loss of $(9.79) million and diluted EPS of $(0.12). The revenue growth was driven by significant increases in IaaS …

Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Barclays PLC has filed an amended Schedule 13G, disclosing a 3.17% beneficial ownership stake in Zentalis Pharmaceuticals Inc. (ZNTL), totaling 2,263,328 shares as of June 30, 2026. This filing indicates that Barclays now holds 5 percent or less of the class. The ownership includes …

Zenith Steel Pipes Posts Modest Q1 FY27 Profit Amid Ongoing Turnaround Efforts

Roadzen Inc. (RDZN) Stock Rises on Q1 2027 Earnings

Citizens Community Bancorp (CZWI) sees Wellington report 0% beneficial stake

Wellington Management Group LLP and its affiliated entities have reported a 0% beneficial ownership stake in Citizens Community Bancorp, Inc. (CZWI) as of June 30, 2026. This Schedule 13G/A filing indicates that Wellington holds no shares with sole or shared voting or dispositive power, …

Zentalis Pharmaceuticals stock falls on public offering news

Zentalis Pharmaceuticals Inc. (NASDAQ:ZNTL) shares dropped 6.5% after announcing an underwritten public stock offering, which will include common stock and pre-funded warrants. The company plans to use the proceeds to fund clinical trials, preclinical studies, regulatory filings, and manufacturing for its oncology programs, particularly …

Zenith Steel Pipes & Industries Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Citizens chief actuary buys $20,590 in company stock

Citizens, Inc. (NASDAQ:CIA) Chief Actuary, Seth Alan Hoxworth, recently purchased 5,376 shares of company stock for $20,590, at $3.83 per share, bringing his direct holdings to over 11,000 shares. This transaction occurred on August 11, 2026, when the stock was near its 52-week low. …

Citizens Capital Markets gains Rheault and Jones, MDs, for syndicate and capital markets biz

Citizens Capital Markets & Advisory has appointed Matt Rheault and Jeff Jones as managing directors in its debt capital markets practice, both previously from Wells Fargo. Jones will lead the firm's asset-backed securities (ABS) and collateralized loan obligation (CLO) capital markets, while Rheault will …

First Citizens BancShares (NASDAQ:FCNCA) Sets New 12-Month High - Here's What Happened

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 6.6% on Disappointing Earnings

Zenas BioPharma (NASDAQ:ZBIO) experienced a 6.6% stock price drop after reporting disappointing quarterly earnings, with an EPS of $(1.77) against an estimated $(1.12) and revenue of $1 million against a $15 million forecast. Despite the earnings miss, analysts generally maintain a "Moderate Buy" rating …

SAB ZENZELE KABILI HOLDINGS (RF) LIMITED – Finalisation announcement in respect of special dividend No. 5

Annexon (NASDAQ:ANNX) Upgraded at Citizens Jmp

Citizens JMP upgraded Annexon (NASDAQ:ANNX) from "underperform" to "market perform," while the overall analyst consensus remains a "Hold" with an average price target of $15.33. The company recently reported a quarterly loss of $0.28 per share, missing consensus estimates. Investors are looking ahead to …

Analysts Just Made A Massive Upgrade To Their Surrozen, Inc. (NASDAQ:SRZN) Forecasts

Analysts have significantly upgraded their near-term forecasts for Surrozen, Inc. (NASDAQ:SRZN), projecting greatly increased statutory revenues and earnings per share for 2026. While revenue is still expected to decline compared to past performance and lag the wider industry, analysts have reduced their loss estimates …

Zenas BioPharma, Inc. 2026: Revenue $1M, Net income ($111.46M), EPS ($1.77) — 10-Q Summary

Zenas BioPharma, Inc. (ZBIO) reported its financial results for the quarter ended 2026, showing revenue of $1M and a net loss of ($111.46M), with a diluted loss per share of ($1.77). These figures represent a significant decrease in revenue and an increase in net …

Form 8K Zenas Biopharma Inc For: 13 August By Investing.com

This article is a brief financial announcement from Investing.com, stating that Zenas Biopharma Inc. filed a Form 8K on August 13th. The filing is related to the company's financial activities and includes the stock symbol ZBIO, which showed a -6.68% change. The content primarily …

ZenaTech Drone Software Maps Grading and Drainage for AI Data Centers

ZenaTech has expanded its ZenaWorx drone-based construction monitoring software to include digital terrain modeling (DTM) capabilities, enabling precise measurement of cut-and-fill volumes, grading accuracy, and drainage for large-scale earthworks. The company announced its first paying customer for an AI data center construction project, targeting …

ZenaTech Buying Galena-Benchmark Engineering To Expand Its Drone Services Platform

ZenaTech has acquired Galena-Benchmark Engineering, a civil engineering and land surveying firm based in Idaho. This acquisition marks ZenaTech's 27th Drone as a Service acquisition and expands its presence to its 13th U.S. state, allowing it to integrate its drone technology into an established …

Earnings Flash (ZBIO) Zenas BioPharma Posts Q2 Loss $1.77 a Share, vs. FactSet Est of $1.12 Loss

Zenas BioPharma (ZBIO) announced a Q2 loss of $1.77 per share, which is significantly wider than FactSet's estimated loss of $1.12 per share. The company reported Q2 revenue of $1.0 million. Zenas BioPharma is a clinical-stage biopharmaceutical company focused on autoimmune diseases with lead …

Zenas BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma announced its second quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of the obexelimab BLA for IgG4-RD with a PDUFA date of May 27, 2027. The company also reported positive Phase 3 INDIGO trial results for obexelimab, …

Earnings Flash (ZBIO) Zenas BioPharma, Inc. Reports Q2 Revenue $1.0M

Zenas BioPharma Reports $111.5 Million Second-Quarter Net Loss

Zenas BioPharma (ZBIO) reported a second-quarter 2026 net loss of $111.5 million on $1.0 million in revenue, an increase from a $52.2 million net loss in the prior-year quarter. The company ended the quarter with $673.9 million in cash and investments, and its biologics …

Citizens Financial Group (NYSE:CFG) Flashes Strong Breakout Setup With Top-Tier Technical Ratings

Wealthcare Advisory Partners LLC Purchases Shares of 12,112 Astrazeneca Plc $AZN

Wealthcare Advisory Partners LLC acquired 12,112 shares of AstraZeneca Plc, valued at approximately $2.3 million, in the second quarter. This move is part of a broader trend of institutional investors increasing their holdings in the pharmaceutical company, which now has 20.35% institutional ownership. AstraZeneca …

Zengame Tech Sets August Board Meeting to Review Interim Results and Dividend

Citizens raises Pharvaris stock price target to $75 on trial progress

Citizens has increased its price target for Pharvaris B.V. to $75.00 from $74.00, maintaining a Market Outperform rating, due to ongoing trial progress. The company's stock has surged 70% in the past year, and key Phase 3 CHAPTER-3 data is expected this quarter. Pharvaris …

Zenith Exports sets Sept 17 e-voting cut-off for 44th AGM

Energized by strong profit growth, Zenergy Battery eyes Shenzhen IPO